CRUCELL AND DSM SIGN RESEARCH LICENSE AGREEMENT WITH CHIRON

Dutch biotechnology company Crucell and allied contract manufacturer DSM Biologics have signed a research license agreement for recombinant protein production with Chiron. This new agreement allows Chiron to evaluate the PER.C6 cell line for use in the manufacturing of Chiron's prophylactic hepatitis C vaccine, which is currently in Phase I clinical trials.